NM23-H1 Monoclonal Antibody

This gene (NME1) was identified because of its reduced mRNA transcript levels in highly metastatic cells. Nucleoside diphosphate kinase (NDK) exists as a hexamer composed of 'A' (encoded by this gene) and 'B' (encoded by NME2) isoforms. Mutations in this gene have been identified in aggressive neuroblastomas. Two transcript variants encoding different isoforms have been found for this gene. Co-transcription of this gene and the neighboring downstream gene (NME2) generates naturally-occurring transcripts (NME1-NME2), which encodes a fusion protein comprised of sequence sharing identity with each individual gene product.

The NM23-H1 Monoclonal Antibody is a highly specialized product that has been developed to target and bind to the NM23-H1 protein. This protein is known to play a critical role in the regulation of cell proliferation and differentiation, making it an important target for research and therapeutic applications.

The NM23-H1 Monoclonal Antibody has been rigorously tested and validated for use in a variety of applications, including Western blotting, immunohistochemistry, and flow cytometry. It is produced using state-of-the-art techniques and is of the highest quality, ensuring reliable and reproducible results.

This product is ideal for researchers and scientists working in the fields of cancer biology, cell signaling, and drug discovery. It offers a powerful tool for investigating the role of the NM23-H1 protein in various cellular processes and for developing new therapies that target this important protein.

Overall, the NM23-H1 Monoclonal Antibody is a valuable resource for any laboratory or research facility looking to advance their understanding of cellular biology and develop new treatments for a range of diseases and conditions.